Brief: Neximmune Announces Preliminary Phase 1/2 Nexi-002 Results In Patients With Multiple Myeloma

Neximmune

12/12/2021 23:47

Dec 12 (Reuters) - Neximmune Inc  NEXI.O :
    * NEXIMMUNE ANNOUNCES PRELIMINARY PHASE 1/2 NEXI-002 RESULTS
IN
PATIENTS WITH MULTIPLE MYELOMA
    * NEXIMMUNE- PHASE 1/2 STUDY OF NEXI-002 AS A MONOTHERAPY IN
PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WHO
FAILED ≥3 PRIOR LINES OF THERAPY IS ONGOING
    * NEXIMMUNE -  THE DATA ON LOW DOSES OF NEXI-002, SHOWED A
PROMISING SAFETY AND TOLERABILITY PROFILE AND EVIDENCE OF
IMMUNOLOGIC AND CLINICAL ACTIVITY

Source text for Eikon:  ID:nGNX3Zqqf0 
Further company coverage:  NEXI.O 

 ((Reuters.Briefs@thomsonreuters.com;))